Literature DB >> 6225866

Pharmacokinetic studies of 5-fluorouracil and 5'-deoxy-5-fluorouridine in rats.

J L Au, J S Walker, Y Rustum.   

Abstract

The pharmacokinetics of 5-fluorouracil (FU) and its metabolic prodrug, 5'-deoxy-5-fluorouridine (dFUR), were investigated in 5- to 9-month-old rats without tumors. Intravenous bolus injections and infusions of FU (25-35 mg X kg-1) and dFUR (500-750 mg X kg-1) had activity against transplanted colon tumors in 2- to 4-month-old rats. Blood and plasma concentrations of FU and dFUR were analyzed by high-pressure liquid chromatography using 5-bromouracil as the internal standard. Free fractions of these drugs in plasma were indistinguishable from unity, indicating little or no protein binding. The area under the blood concentration-time profiles and the steady-state concentrations of unchanged dFUR were 40- to 100-fold higher than those of unchanged FU. The respective blood clearances of FU and dFUR were 44 and 18 ml X kg-1 X min-1 after i.v. bolus injections, which were significantly lower than the 108 and 26 ml X kg-1 X min-1 after infusion. FU clearance decreased when its infusion rate was increased from 25 to 50 mg X kg-1 X day-1. Renal clearances of both drugs remained the same after either route of administration. These data suggest that both drugs were eliminated by nonlinear kinetics and that their metabolism was saturated at a more rapid administration rate.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6225866

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  11 in total

1.  Effects of 5-fluorouracil, leucovorin, and glucarate in rat colon-tumor explants.

Authors:  T D Schmittgen; A Koolemans-Beynen; T E Webb; T J Rosol; J L Au
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

2.  Effect of uridine coadministration on 5'-deoxy-5-fluorouridine disposition in rats.

Authors:  J L Au; M G Wientjes; S L Bramer
Journal:  Cancer Chemother Pharmacol       Date:  1988       Impact factor: 3.333

3.  Pharmacokinetic study of doxifluridine given by 5-day stepped-dose infusion.

Authors:  P A Reece; I N Olver; R G Morris; J F Bishop; T W Guentert; H S Hill; B L Hillcoat
Journal:  Cancer Chemother Pharmacol       Date:  1990       Impact factor: 3.333

4.  5-Fluorouracil-metronidazole combination therapy in metastatic colorectal cancer. Clinical, pharmacokinetic and in vitro cytotoxicity studies.

Authors:  Z Bardakji; J Jolivet; Y Langelier; J G Besner; J Ayoub
Journal:  Cancer Chemother Pharmacol       Date:  1986       Impact factor: 3.333

5.  Effect of coadministered uridine on intestinal first-pass metabolism of 5'-deoxy-5-fluorouridine in conscious rats--an evaluation by method of portal-systemic concentration difference.

Authors:  Y Sawai; K Yamaoka; T Nakagawa
Journal:  Pharm Res       Date:  1998-07       Impact factor: 4.200

6.  Biologic activity of 5'-deoxy-5-fluorouridine by rectal administration.

Authors:  S L Bramer; L C Gunnarsson; J L Au
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

7.  Absorption of 5'-deoxy-5-fluorouridine from colon.

Authors:  J L Au; L C Gunnarsson
Journal:  Pharm Res       Date:  1989-04       Impact factor: 4.200

8.  Inhibition of intestinal pyrimidine nucleoside phosphorylases.

Authors:  M G Wientjes; J L Au
Journal:  Pharm Res       Date:  1987-10       Impact factor: 4.200

9.  Pharmacokinetics of 5-fluorouracil infusions in the rat: comparison with man and other species.

Authors:  J M Collins
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

10.  Effect of age on the disposition and tissue clearances of fluorinated pyrimidines in rats.

Authors:  J L Au
Journal:  Pharm Res       Date:  1985-11       Impact factor: 4.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.